Sigan Hartley, PhD – Slide of the Week

There is a critical need to identify measures of cognitive functioning sensitive to early Alzheimer’s disease (AD) pathophysiology in Down syndrome to advance clinical trial research in this at-risk population. The objective of the study was to longitudinally track performance on cognitive measures in relation to neocortical and striatal amyloid beta (Aβ) in non-demented Down syndrome.

New NIH-funded initiative will examine Alzheimer’s disease in people with Down syndrome

A team of researchers at the University of Wisconsin–Madison is part of a new multi-institution effort to better understand Alzheimer’s disease in adults with Down syndrome. Adults with Down syndrome are at high risk for …

Mancheski Foundation Funds Next-Gen Research on Down Syndrome and Alzheimer’s

A gift from the Mancheski Foundation continues to provide integral support to doctoral student Matthew Zammit as he furthers his research on the progression of Alzheimer’s disease in individuals with Down syndrome. Zammit is beginning …

Bradley T Christian, PhD – Slide of the Week

 Individuals with Down syndrome (DS) are at increased risk of developing Alzheimer’s disease (AD) and show the earliest signs of amyloid-β (Aβ) deposition in the striatum. The metric for tracking Aβ burden using PET radiotracers frequently uses average standard uptake value ratios (SUVr) in signature regions of the brain specific to Aβ deposition.